Todd Henderson, MD
Critical Care Medicine · Southaven, MSNPI 1710163050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,208 and has fallen 51.6% since, to $584 in 2025. Among critical care medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$828
- Actelion Pharmaceuticals US, Inc.$548
- AstraZeneca$502
- Insmed, Inc.$426
- Boehringer Ingelheim$339
- Genentech USA, Inc.$336
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,04297%
- Education$1693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $828 |
| Actelion Pharmaceuticals US, Inc. | 32 | $548 |
| AstraZeneca(2 entities) | 18 | $502 |
| Insmed, Inc. | 17 | $426 |
| Boehringer Ingelheim | 15 | $339 |
| Genentech USA, Inc. | 13 | $336 |
| Merck | 5 | $271 |
| Sanofi | 9 | $265 |
| Harmony Biosciences LLC | 8 | $218 |
| Mallinckrodt Hospital Products Inc. | 6 | $189 |
| Jazz Pharmaceuticals Inc. | 9 | $176 |
| ZOLL Respicardia, Inc. | 2 | $141 |
| Grifols USA, LLC | 10 | $128 |
| Mylan Specialty L.p. | 7 | $114 |
| La Jolla Pharmaceutical Company | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 3 | $88 |
| Bayer | 5 | $83 |
| Electromed, Inc. | 6 | $70 |
| United Therapeutics Corporation | 4 | $64 |
| Gilead | 1 | $31 |
| Amgen | 2 | $31 |
| Shionogi Inc | 1 | $29 |
| Novartis | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Intuitive Surgical | 1 | $22 |
| CSL Behring | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Baxter Healthcare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WINREVAIR$225
- remede System$121
- FASENRA$117
- OFEV$116
- BREZTRI$105
How this compares
$5,211 in reported general payments places this provider in the 90th percentile of 23 critical care medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 27 | $635,963 |
| OpsumitMacitentan | 36 | $455,578 |
| OfevNintedanib Esylate | 13 | $171,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $107,027 |
| Dupixent PenDupilumab | 12 | $43,869 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,746 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,481 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,883 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $3,852 |
| Sildenafil Citrate | 23 | $3,537 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,164 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,060 |
| Azithromycin | 45 | $497 |
| Omeprazole | 37 | $268 |
| Fluticasone Propionate | 23 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $548 | $1,091,54163 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $339 | $182,29227 claims |
| GSKTrelegy Ellipta | $828 | $107,027134 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $502 | $17,62936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 critical care medicine providers in Mississippi.
Other critical care medicine in Southaven
- Emily BrumfieldJackson$14K
- Robert WalleyHattiesburg$8K
- Lekha DeereJackson$5K
- Geeta GyamlaniJackson$3K
- Lauren BeasleyColumbus$3K
- Ryain AlexanderRipley$2K
- Wade ChristopherJackson$2K
- Daniel CastilloJackson$2K
- Christopher SwiftMeridian$986
- Joe PresslerHattiesburg$946
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.